Cover Image
市場調查報告書

深部靜脈血栓症 (DVT):開發中產品分析

Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192548
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
深部靜脈血栓症 (DVT):開發中產品分析 Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 33 Pages
簡介

深部靜脈血栓症是指人體深處某靜脈出現的血栓,主要發生在小腿和大腿的大靜脈。主要的症狀,是皮膚變色 (帶紅色) 和下肢痛,下肢的腫脹 (水腫) 、皮膚溫度上升。易罹病素質中包含著年齡和抽煙,先天性的血栓障礙,外傷或外科手術痕,癌症,發炎性腸道疾病,心臟衰竭等。主要的治療藥,有血栓溶解劑和抗凝固劑等。

本報告提供全球各國的深部靜脈血栓症(DVT)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

深部靜脈血栓症 (DVT)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

深部靜脈血栓症 (DVT):企業開發中的治療藥

深部靜脈血栓症 (DVT):大學/機關研究中的治療藥

深部靜脈血栓症 (DVT):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

深部靜脈血栓症 (DVT):企業開發中的產品

深部靜脈血栓症 (DVT):大學/機關研究中的產品

深部靜脈血栓症 (DVT的)治療藥的開發企業

  • 3SBio Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Generex Biotechnology Corporation
  • Laboratorios Farmaceuticos Rovi, S.A.

深部靜脈血栓症 (DVT):治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

深部靜脈血栓症 (DVT):最近的開發平台趨勢

深部靜脈血栓症 (DVT):暫停中的計劃

深部靜脈血栓症 (DVT):開發中止的產品

深部靜脈血栓症 (DVT):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9118IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2017, provides an overview of the Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline landscape.

Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema) and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease and heart failure. Treatment includes thrombolytic and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I and Preclinical stages are 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Deep Vein Thrombosis (DVT) - Overview
    • Deep Vein Thrombosis (DVT) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Deep Vein Thrombosis (DVT) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Dong-A Socio Holdings Co Ltd
    • F. Hoffmann-La Roche Ltd
    • Generex Biotechnology Corp
    • Laboratorios Farmaceuticos Rovi SA
  • Deep Vein Thrombosis (DVT) - Drug Profiles
    • Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-20201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enoxaparin sodium biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fondaparinux sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-023725 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Deep Vein Thrombosis (DVT) - Dormant Projects
  • Deep Vein Thrombosis (DVT) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Deep Vein Thrombosis (DVT) - Pipeline by 3SBio Inc, H1 2017
  • Deep Vein Thrombosis (DVT) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corp, H1 2017
  • Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi SA, H1 2017
  • Deep Vein Thrombosis (DVT) - Dormant Projects, H1 2017
  • Deep Vein Thrombosis (DVT) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Deep Vein Thrombosis (DVT), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top